MS 1-2

structure given in first source

Also Known As:

MC 1-2; MS-1-2; N-(4-phenoxyethyl-1-piperazinomethyl)-1,4-benzodioxane-2-carboxamide dihydrochloride; 1,4-Benzodioxin-2-carboxamide, 2,3-dihydro-N-((4-(2-phenoxyethyl)-1-piperazinyl)methyl)-, trans-

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Dioxanes
    - MS 1-2: 8

Experts

1.	Breithardt, G: 2 articles (01/2004 - 09/2001)
2.	Haverkamp, W: 2 articles (01/2004 - 09/2001)
3.	Schulze-Bahr, E: 2 articles (01/2004 - 09/2001)
4.	Wedekind, H: 2 articles (01/2004 - 09/2001)
5.	Demirçelik, B M: 1 article (03/2014)
6.	Doger, C: 1 article (03/2014)
7.	Duran, M: 1 article (03/2014)
8.	Kahveci, K: 1 article (03/2014)
9.	Kurtul, A: 1 article (03/2014)
10.	Murat, S: 1 article (03/2014)

Related Diseases

1.	Infarction (Infarctions) 08/01/2003 - "2. LF 16-0687 Ms (1, 2 and 4 mg kg(-1)) administered 0.5 h before and, 1.25 and 6 h after MCAO, decreased the infarct volume by a maximum of 33% and significantly improved the neurological recovery. "
2.	Ventricular Tachycardia 09/04/2001 - "In the surface ECG soon after birth, a prolonged QTc interval (600 ms(1/2)) and polymorphic ventricular tachyarrhythmias were documented. " 03/01/2014 - "However, the patients with sustained ventricular tachycardia (VT), prolonged VT and sustained AIVR had higher corrected QTd (92 ms 1/2 , 97.8 ms 1/2 , 81.7 ms 1/2 , respectively) than the patients without these arrhythmias (74 ms 1/2 , 56.3 ms 1/2 , 58.28 ms 1/2 , respectively) (P = 0.022, 0.013, 0.018). "
3.	Syncope (Fainting) 05/01/2008 - "These patients displayed prolonged QTc intervals (629, 508, and 500 ms(1/2,) respectively) and repetitive episodes of syncope, but no deafness. " 05/01/2005 - "We enrolled 27 symptomatic patients with LQTS undergoing ICD therapy (QTc 540 +/- 64 ms(1/2); 85% female, 63% cardiac arrest; 33% syncope despite beta-blockers; 4% with severe phenotype) and 81 genotyped patients with LQTS undergoing conventional drug therapy (28 LQT1, 39 LQT2, 1 LQT3, 13 LQT5). "
4.	Atrioventricular Block 01/01/2004 - "Intrauterine and neonatal manifestations of congenital long QT syndrome are associated with a high cardiac risk, particularly when atrioventricular block and excessive QT prolongation (> 600 ms(1/2)) are present. " 01/01/2004 - "Disappearance of the 2:1 atrioventricular block and QTc shortening (from 740 ms(1/2) to 480 ms(1/2)), however, was achieved when mexiletine was added to propranolol. "
5.	Accelerated Idioventricular Rhythm 03/01/2014 - "However, the patients with sustained ventricular tachycardia (VT), prolonged VT and sustained AIVR had higher corrected QTd (92 ms 1/2 , 97.8 ms 1/2 , 81.7 ms 1/2 , respectively) than the patients without these arrhythmias (74 ms 1/2 , 56.3 ms 1/2 , 58.28 ms 1/2 , respectively) (P = 0.022, 0.013, 0.018). "

Related Drugs and Biologics

1.	LF 16-0687
2.	Propranolol (Inderal)
3.	Mexiletine (Mexitil)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)